Loading
companiesCompany
Mast Therapeutics
Mast, earlier called ADVENTRX, was a San Diego biotech whose fluorouracil modulator CoFactor reached phase 3 in colorectal cancer and failed; it later pursued sickle cell disease and merged into Savara in 2017.
Also called: Mast Therapeutics, Inc.ADVENTRX PharmaceuticalsSavara
Overview
Mast Therapeutics, formerly ADVENTRX Pharmaceuticals, developed ANX-510 (CoFactor), a folate analogue intended to enhance fluorouracil, through a phase 3 trial in metastatic colorectal cancer that did not show benefit, and later vepoloxamer for sickle cell crisis and heart failure, which also failed in phase 3. The company merged with Savara in 2017. Its trials remain on ClinicalTrials.gov under Mast and ADVENTRX as lead sponsor.
Headquarters
San Diego, CA, US
Scorecard
All companies#131of 1244 companies, score 44
- approved products +6
- modalities +2
- regions +6
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 3,996 registry studies. Formula on the scorecards page.
Type
Stage
Acquired
Website
ApprovedFluoropyrimidine antimetabolite
Fluorouracil (5-FU) · Adrucil / Efudex
The 1957 chemotherapy that remains the backbone of treatment for bowel, stomach, pancreatic, anal, head and neck and breast cancers, and as a cream for skin precancers.
Similar pages
- CompanyNorgine
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer.
- CompanyZeria Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed